drugset / Trial / NCT03577028
Study of HPN424 in Patients With Advanced Prostate Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
An open-label, Phase 1/2a, study of HPN424 as monotherapy to assess the safety, tolerability and PK in patients with advanced prostate cancer refractory to androgen therapy
Timeline
- Start
- 2018-07-24
- Primary completion
- 2023-02-27
- Completion
- 2023-02-27
Outcome
Outcome not reported
Stopped: “Decision not to continue to the expansion portion of the study”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HPN424 | Unknown | 1.3 ng | Intravenous |
| Subject | HPN424 | Unknown | 36 ng | Intravenous |
| Subject | HPN424 | Unknown | 120 ng | Intravenous |
| Subject | HPN424 | Unknown | 150 ng | Intravenous |
| Subject | HPN424 | Unknown | 225 ng | Intravenous |
| Subject | HPN424 | Unknown | 300 ng | Intravenous |
| Subject | HPN424 | Unknown | 450 ng | Intravenous |